Denmark urges EU to tighten Russian visa restrictions after alleged assassination plot
Denmark has urged European Union countries to introduce tougher travel restrictions on Russian nationals following allegations that Moscow's in...
An analysis of U.S. health claims reveals that while GLP-1 drugs like Wegovy may aid weight loss, they significantly increase medical costs—rising to $18,507 annually—without reducing obesity-related health events, raising concerns for insurers and employers.
An analysis of U.S. health insurance claims shared with Reuters indicates that while medications like Wegovy may help reduce weight, they do not lower medical expenses.
After two years of treatment with Novo Nordisk’s Wegovy or other GLP-1 drugs, the average annual cost of care for patients with obesity rose to $18,507- a 46% increase from the prior average of $12,695. This data, provided by pharmacy benefits manager Prime Therapeutics, highlights the financial implications of obesity treatment.
In a control group of patients not taking GLP-1 drugs, costs increased by 14% over the same period. For those on GLP-1 medications, the rise in expenses was mainly due to higher prescription drug costs, though medical costs also grew. The analysis found no decrease in obesity-related medical events - such as heart attacks, strokes, or type 2 diabetes diagnoses -compared to the control group.
Novo Nordisk and Eli Lilly, makers of the GLP-1 weight-loss drug Zepbound, have earned billions since their U.S. launches. While they claim that their medications could reduce healthcare costs linked to obesity, many U.S. employers and officials hesitate to cover these effective but costly treatments due to high upfront expenses and uncertain future savings.
"The budget hit here is frightening for a lot of governments and private entities," said Ben Ippolito, an economist at the American Enterprise Institute. He noted that the potential demand for these drugs is immense. Analysts predict the weight-loss drug market could reach $150 billion annually in the next decade.
Novo Nordisk emphasized that treating obesity is associated with improved medical outcomes, even though officials have not yet determined how to quantify these savings. Eli Lilly did not respond to a request for comment.
A study by Prime Therapeutics found that only one-in-four patients prescribed GLP-1 drugs like Wegovy or Ozempic for weight loss continued taking them after two years, leading to concerns about the cost-effectiveness of these medications.
With an estimated additional expense of $11,200 per patient in the first two years, Prime cautioned that without sustained use and positive health outcomes, insurers may need to reconsider their coverage of these weight-loss drugs.
European leaders backing Ukraine met in Berlin on Thursday 19 November and warned that no peace deal should be settled without them.
Three people have been killed and around 15 injured after Russian ballistic missiles struck three bridges over the Dnipro River in Kyiv, according to the Ukrainian capital’s mayor, Vitali Klitschko.
Azerbaijani President Ilham Aliyev met Vietnamese Prime Minister Le Minh Hung in Hanoi on 20 November, during a visit highlighting the longstanding friendship and growing strategic partnership between the two countries.
Britain and the European Union have reached an agreement to ease trade, expand opportunities for young people and deepen economic ties, in a major step towards rebuilding relations after Brexit.
Georgia has declared 22 November 2026 a national day of mourning following a deadly residential building collapse in the Kvemo Ponichala district of Tbilisi.
For the first time in more than a quarter of a century, the United States can no longer say it has eliminated measles as health experts warn the American outbreak reflects a collapse in trust in vaccines.
A new study in mice suggests the brain’s protective barrier does more than block harmful substances. It also delivers essential proteins from the body, a process that may break down early in Alzheimer’s disease and offer a new target for treatment.
Here's your AnewZ Daily Brief for the 5th of November, as health emergencies, humanitarian crises, political shifts, and cybersecurity threats put governments and essential services under pressure across the globe. Here are five stories worth your attention.
Kazakhstan plans to manufacture 494 types of medicines through eight major investment projects worth a combined $862 million, Health Minister Akmaral Alnazarova announced on 3 November, local media reported.
Dengue fever has killed more people in Bangladesh this year than in the whole of 2025, with October the deadliest month so far, data from Bangladesh's Health Ministry shows.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment